Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radical Prostatectomy Clear all
Completed Phase 3 Interventional

Evaluating the Effect of the VCD on Erectile Function and Penile Length Post RRP

NCT00177125
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatectomy
Interventions
ErectAid
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

NCT00450749
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene
Other · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 18, 2026, 6:04 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

NCT00860158
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
Drug · Procedure
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Scottsdale, Arizona • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Not applicable Interventional

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

NCT02080689
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher
Other
Lead sponsor
GenomeDx Biosciences Corp
Industry
Eligibility
Male only
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Anchorage, Alaska • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 18, 2026, 6:04 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy

NCT07564102
View directory record Official record
Conditions
Prostate Cancer
Interventions
dMD-002, Control
Device · Other
Lead sponsor
Mochida Medical USA, Inc.
Industry
Eligibility
40 Years to 74 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 18, 2026, 6:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NCT05678322
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 18, 2026, 6:04 AM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Prostatectomy

NCT04206280
View directory record Official record
Conditions
Prostate Cancer, Ambulation Difficulty
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02830165
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 3 Interventional

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

NCT00589472
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 2 Interventional

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

NCT00090376
View directory record Official record
Conditions
Impotence, Prostate Cancer
Interventions
GPI 1485
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years to 69 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
25
States / cities
Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2008 · Synced Oct 18, 2026, 6:04 AM EDT
Active, not recruiting Phase 2 Interventional

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT03899987
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Procedure · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of the AMS CONTINUUM™ Device

NCT00894933
View directory record Official record
Conditions
Prostate Cancer
Interventions
CONTINUUM™
Device
Lead sponsor
American Medical Systems
Industry
Eligibility
40 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Burlington, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

NCT00888654
View directory record Official record
Conditions
Prostate Cancer
Interventions
B-Dim, Radical Prosatectomy
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 18, 2026, 6:04 AM EDT
Withdrawn No phase listed Observational

Study of Anatomic Nerve Sparing Radical Perineal Prostatectomy

NCT00922818
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 18, 2026, 6:04 AM EDT
Not yet recruiting Phase 1 Interventional

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

NCT07860255
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pasritamig
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 6:04 AM EDT
Terminated Phase 2 Interventional Results available

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

NCT04030559
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions
Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 6:04 AM EDT
Completed No phase listed Observational

Data Collection Post Radical Prostatectomy

NCT06351579
View directory record Official record
Conditions
Stress Urinary Incontinence, Radical Prostatectomy, BPH
Interventions
Control
Other
Lead sponsor
Levee Medical, Inc.
Industry
Eligibility
45 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 18, 2026, 6:04 AM EDT
Active, not recruiting Not applicable Interventional

Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy

NCT04299620
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Digital Image Analysis, Radical Prostatectomy, Transrectal Ultrasound
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 18, 2026, 6:04 AM EDT
Completed Phase 2Phase 3 Interventional

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

NCT00765479
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy protein isolate, placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 18, 2026, 6:04 AM EDT
Terminated Phase 4 Interventional Results available

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

NCT03006562
View directory record Official record
Conditions
Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Subcutaneous Heparin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 18, 2026, 6:04 AM EDT
Recruiting Phase 2 Interventional

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

NCT06022822
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
Procedure · Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 18, 2026, 6:04 AM EDT
Not listed No phase listed Observational

Characterization of Prostate Cancer With 3T MR

NCT00831142
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 18, 2026, 6:04 AM EDT